Erasca Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that, in connection with the appointment of Charles S. Fuchs, M.D., M.P.H., as president of research and development, Erasca’s Board of Directors has approved the grant of inducement awards.

The Board of Directors approved the grant to Dr. Fuchs of non-qualified stock options to purchase 1,278,520 shares of Erasca common stock under the company’s 2026 Employment Inducement Incentive Award Plan (the “Inducement Plan”), 25% of which will vest on August 10, 2027, and the remainder of which will vest in 36 equal monthly installments thereafter. The stock options were granted on August 10, 2026 with an exercise price equal to the closing price of Erasca’s common stock on the Nasdaq Global Select Market on the grant date.